Date	e:2022/2/2	4					
You	r Name: Yan Li	u					
Mar	Manuscript Title: Trends and frontiers of research on pharmacoeconomics from 2012–2021: a scientometric						
	lysis						
Mar	nuscript number (if known):		·				
rela part to to to rela  The mar  The to	ted to the content of your name ites whose interests may be ransparency and does not not interest, it following questions apply the content only.  author's relationships/active epidemiology of hyperterication, even if that medical	nanuscript. "Related" mea affected by the content of ecessarily indicate a bias. is preferable that you do the author's relationship vities/interests should be g nsion, you should declare tion is not mentioned in t	os/activities/interests as they relate to the <u>current</u> defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive				
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)				
		needed) Time frame: Since the initia	I planning of the work				
4	All C	ı	n planning of the work				
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone					
		<b></b> :	25				
2	Cranta ar contracts from	Time frame: pas	136 months				
2	Grants or contracts from any entity (if not indicated	XNone					
	in item #1 above).						
3	Royalties or licenses	XNone					
1	Consulting food	V None					
4	Consulting fees	XNone					

-		V N	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V 1	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/2/2	4	
You	r Name: Zheny	an Bo	
	nuscript Title: Trends an ysis	nd frontiers of research o	n pharmacoeconomics from 2012–2021: a scientometric
Man	uscript number (if known):		
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" me affected by the content o ecessarily indicate a bias.	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment of the series of the manuscript. If you are in doubt about whether to list a poso.
	following questions apply touscript only.	o the author's relationshi	ips/activities/interests as they relate to the <u>current</u>
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.
	em #1 below, report all sup time frame for disclosure is	-	ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as needed)	Specifications/Comments (e.g., if payments were made to you or to your institution)
		Time frame: Since the initi	ial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
2		Time frame: pas	st 36 months
2	Grants or contracts from any entity (if not indicated	XNone	
	in item #1 above).		
3	Royalties or licenses	XNone	

Consulting fees

_		V 1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending	XNone	
	periumg		
9	Participation on a Data	X None	
,	Safety Monitoring Board or	X_None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,	XNone	
	committee or advocacy		
	· · · · · · · · · · · · · · · · · · ·		
11	group, paid or unpaid	V Name	
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/2/2	4				
You	r Name: Dan L	iu				
	Nanuscript Title: Trends and frontiers of research on pharmacoeconomics from 2012–2021: a scientometric nalysis					
	nuscript number (if known):					
rela part to ti	ted to the content of your n ies whose interests may be	nanuscript. "Related" mea affected by the content o ecessarily indicate a bias.	relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third f the manuscript. Disclosure represents a commitment If you are in doubt about whether to list a so.			
	following questions apply touscript only.	o the author's relationship	ps/activities/interests as they relate to the <u>current</u>			
to tl	• •	nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive he manuscript.			
	em #1 below, report all sup time frame for disclosure is	-	d in this manuscript without time limit. For all other items,			
		Name all entities with	Specifications/Comments			
		whom you have this	(e.g., if payments were made to you or to your			
		relationship or indicate	institution)			
		none (add rows as				
		needed) Time frame: Since the initia	al planning of the work			
1	All support for the present	X None	ar planning of the work			
_	manuscript (e.g., funding,					
	provision of study materials,					
	medical writing, article					
	processing charges, etc.)					
	No time limit for this item.					
		Time frame: pas	t 36 months			
2	Grants or contracts from	XNone				
	any entity (if not indicated					
2	in item #1 above).	V. Name				
3	Royalties or licenses	XNone				

Consulting fees

-		V N	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V 1	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:	2022/2/24
	Sha Diao
Manuscript Title: analysis	Trends and frontiers of research on pharmacoeconomics from 2012–2021: a scientometr
Manuscript numbe	r (if known):
related to the conto parties whose inter to transparency and relationship/activit	ansparency, we ask you to disclose all relationships/activities/interests listed below that are ent of your manuscript. "Related" means any relation with for-profit or not-for-profit third rests may be affected by the content of the manuscript. Disclosure represents a commitmen d does not necessarily indicate a bias. If you are in doubt about whether to list a cy/interest, it is preferable that you do so.
The following ques manuscript only.	tions apply to the author's relationships/activities/interests as they relate to the <u>current</u>

The author's relationships/activities/interests should be <u>defined broadly</u>. For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.

In item #1 below, report all support for the work reported in this manuscript without time limit. For all other items, the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed)  Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)  planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	
		Time frame: past	36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	
4	Consulting fees	XNone	

-		V N	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V 1	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/2/	24		
Your	· Name: Chur	nsong Yang	_	
		nd frontiers of research on pharmacoeconomics from 2012–2021: a scientometric		
	ysis userint number (if known)			
ivian	uscript number (if known	l:		
relat parti to tr	ed to the content of your ies whose interests may b ansparency and does not	, we ask you to disclose all relationships/activities/interests listed below the manuscript. "Related" means any relation with for-profit or not-for-profit the affected by the content of the manuscript. Disclosure represents a commit necessarily indicate a bias. If you are in doubt about whether to list a it is preferable that you do so.	hird	
	following questions apply uscript only.	to the author's relationships/activities/interests as they relate to the <u>currer</u>	<u>nt</u>	
to th	e epidemiology of hypert	ivities/interests should be <u>defined broadly</u> . For example, if your manuscript ension, you should declare all relationships with manufacturers of antihype ation is not mentioned in the manuscript.	-	
	em #1 below, report all su ime frame for disclosure i	pport for the work reported in this manuscript without time limit. For all ot s the past 36 months.	her items	
		Name all entities with Specifications/Comments		
		whom you have this (e.g., if payments were made to you or to your		
		relationship or indicate institution)		
		none (add rows as		
		needed)		
		Time frame: Since the initial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials,	X_None		
	medical writing, article			
	processing charges, etc.)  No time limit for this item.			
	No time inint for this item.			
		Time frame: past 36 months		
2	Grants or contracts from	X None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	X None		
	Royalties of licenses	XNone		
	Royalties of licenses			

Consulting fees

		I			
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	X None			
	pending				
	F 5.1.0.1.0				
9	Participation on a Data	X None			
,	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
_	financial interests				
Dloa	Please summarize the above conflict of interest in the following boy:				

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/2/2	4	
You	r Name: Hailor	ng Li	
	<del></del>	nd frontiers of research o	on pharmacoeconomics from 2012–2021: a scientometric
	ysis		
Man	uscript number (if known):		
relat part to tr	ted to the content of your n ies whose interests may be	nanuscript. "Related" me affected by the content ecessarily indicate a bias	Il relationships/activities/interests listed below that are eans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment . If you are in doubt about whether to list a o so.
	following questions apply t uscript only.	o the author's relationsh	ips/activities/interests as they relate to the <u>current</u>
to the med	ne epidemiology of hyperter lication, even if that medica	nsion, you should declare tion is not mentioned in port for the work reporte	e <u>defined broadly</u> . For example, if your manuscript pertains e all relationships with manufacturers of antihypertensive the manuscript.  ed in this manuscript without time limit. For all other items,
		Name all entities with whom you have this relationship or indicate none (add rows as	Specifications/Comments (e.g., if payments were made to you or to your institution)
		needed)	
		Time frame: Since the init	tial planning of the work
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)	XNone	
	No time limit for this item.		
		Time frame: pa	ast 36 months
2	Grants or contracts from any entity (if not indicated in item #1 above).	XNone	
3	Royalties or licenses	XNone	

\_X\_\_None

Consulting fees

-		V N	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events	V 1	
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending		
9	Participation on a Data	XNone	
	Safety Monitoring Board or		
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	·		
12	Receipt of equipment,	X None	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/2/2	4		
You	r Name: Linan	Zeng		
Man	uscript Title: Trends a	and frontiers of research on pharmacoeconomics from 2012–2021: a scientometric		
	ysis			
Man	uscript number (if known):			
relat part to tr	ted to the content of your r ies whose interests may be	nanuscript. "Related" me affected by the content o ecessarily indicate a bias	I relationships/activities/interests listed below that are ans any relation with for-profit or not-for-profit third of the manuscript. Disclosure represents a commitment. If you are in doubt about whether to list a poso.	
	following questions apply t uscript only.	o the author's relationsh	ips/activities/interests as they relate to the <u>current</u>	
to th		nsion, you should declare	defined broadly. For example, if your manuscript pertains all relationships with manufacturers of antihypertensive the manuscript.	
	em #1 below, report all sup time frame for disclosure is	-	ed in this manuscript without time limit. For all other items,	
		Name all entities with	Specifications/Comments	
		whom you have this	(e.g., if payments were made to you or to your	
		relationship or indicate	institution)	
		none (add rows as		
		needed)		
		Time frame: Since the init	ial planning of the work	
1	All support for the present	XNone		
	manuscript (e.g., funding,			
	provision of study materials,			
	medical writing, article processing charges, etc.)			
	No time limit for this item.			
	to time inner for time item.			
		Time frame: pa	st 36 months	
2	Grants or contracts from	X None		
	any entity (if not indicated			
	in item #1 above).			
3	Royalties or licenses	XNone		

Consulting fees

_		V 1	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending	XNone	
	periumg		
9	Participation on a Data	X None	
,	Safety Monitoring Board or	X_None	
	Advisory Board		
10	Leadership or fiduciary role	X None	
10	in other board, society,		
	committee or advocacy		
	· · · · · · · · · · · · · · · · · · ·		
11	group, paid or unpaid	V Name	
11	Stock or stock options	XNone	
12	Receipt of equipment,	XNone	
	materials, drugs, medical		
	writing, gifts or other		
	services		
13	Other financial or non-	XNone	
	financial interests		

None			

Please place an "X" next to the following statement to indicate your agreement:

Date	e:2022/2/2	24			
You	r Name: Qin Y	u			
	nuscript Title: Trends a ysis	nd frontiers of research on pharmacoeconomics from 2012–2021: a scientometric			
	nuscript number (if known)	:			
	,				
rela part to ti	ted to the content of your i	manuscript. "Related" me affected by the content ecessarily indicate a bia	all relationships/activities/interests listed below that are leans any relation with for-profit or not-for-profit third to fit of the manuscript. Disclosure represents a commitment s. If you are in doubt about whether to list a do so.		
	following questions apply touscript only.	to the author's relationsl	hips/activities/interests as they relate to the <u>current</u>		
to tl		nsion, you should declar	e <u>defined broadly</u> . For example, if your manuscript pertains re all relationships with manufacturers of antihypertensive in the manuscript.		
	em #1 below, report all sup time frame for disclosure is		ted in this manuscript without time limit. For all other items		
		Name all entities with	Specifications/Comments		
		whom you have this	(e.g., if payments were made to you or to your		
		relationship or indicate	institution)		
		none (add rows as			
		needed)			
		Time frame: Since the ini	itial planning of the work		
1	All support for the present manuscript (e.g., funding, provision of study materials,	XNone			
	medical writing, article				
	processing charges, etc.)  No time limit for this item.				
	No time limit for this item.				
		Time frame: n	past 36 months		
2	Grants or contracts from		past 36 months		
2	Grants or contracts from any entity (if not indicated	Time frame: p	east 36 months		
2			past 36 months		
2	any entity (if not indicated		east 36 months		
	any entity (if not indicated in item #1 above).	XNone	east 36 months		

Consulting fees

		I			
5	Payment or honoraria for	XNone			
	lectures, presentations,				
	speakers bureaus,				
	manuscript writing or				
	educational events				
6	Payment for expert	XNone			
	testimony				
7	Support for attending	XNone			
	meetings and/or travel				
8	Patents planned, issued or	X None			
	pending				
	F 5.1.0.1.0				
9	Participation on a Data	X None			
,	Safety Monitoring Board or				
	Advisory Board				
10	Leadership or fiduciary role	X None			
	in other board, society,				
	committee or advocacy				
	group, paid or unpaid				
11	Stock or stock options	X None			
12	Receipt of equipment,	X None			
	materials, drugs, medical				
	writing, gifts or other				
	services				
13	Other financial or non-	X None			
_	financial interests				
Dloa	Please summarize the above conflict of interest in the following boy:				

None			

Please place an "X" next to the following statement to indicate your agreement:

Date:2022/2/24
Your Name: Lingli Zhang
Manuscript Title: Trends and frontiers of research on pharmacoeconomics from 2012–2021: a scientometric
Manuscript number (if known):
In the interest of transparency, we ask you to disclose all relationships/activities/interests listed below that are related to the content of your manuscript. "Related" means any relation with for-profit or not-for-profit third parties whose interests may be affected by the content of the manuscript. Disclosure represents a commitment to transparency and does not necessarily indicate a bias. If you are in doubt about whether to list a relationship/activity/interest, it is preferable that you do so.
The following questions apply to the author's relationships/activities/interests as they relate to the <u>current</u> manuscript only.
The author's relationships/activities/interests should be <u>defined broadly</u> . For example, if your manuscript pertains to the epidemiology of hypertension, you should declare all relationships with manufacturers of antihypertensive medication, even if that medication is not mentioned in the manuscript.
n item #1 below, report all support for the work reported in this manuscript without time limit. For all other item the time frame for disclosure is the past 36 months.

		Name all entities with whom you have this relationship or indicate none (add rows as needed) Time frame: Since the initial	Specifications/Comments (e.g., if payments were made to you or to your institution)
1	All support for the present manuscript (e.g., funding, provision of study materials, medical writing, article processing charges, etc.)  No time limit for this item.	XNone	pranning or the work
2	Grants or contracts from any entity (if not indicated	Time frame: pastXNone	36 months
3	in item #1 above).  Royalties or licenses	XNone	
4	Consulting fees	XNone	

		I	
5	Payment or honoraria for	XNone	
	lectures, presentations,		
	speakers bureaus,		
	manuscript writing or		
	educational events		
6	Payment for expert	XNone	
	testimony		
7	Support for attending	XNone	
	meetings and/or travel		
8	Patents planned, issued or	X None	
	pending	XNone	
	periamg		
9	Participation on a Data	X None	
	Safety Monitoring Board or	XNone	
	Advisory Board		
10	Leadership or fiduciary role	X None	
	in other board, society,		
	committee or advocacy		
	group, paid or unpaid		
11	Stock or stock options	X None	
	Stock of Stock options		
12	Receipt of equipment,	X None	
12	materials, drugs, medical	XNONE	
	writing, gifts or other		
	services		
13	Other financial or non-	X None	
	financial interests		
Dlos	see summarize the above se	nflict of interest in the	following hov:

None			

Please place an "X" next to the following statement to indicate your agreement: